FCCC LOGO Faculty Publications
Mohler JL , Armstrong AJ , Bahnson RR , D'Amico AV , Davis BJ , Eastham JA , Enke CA , Farrington TA , Higano CS , Horwitz EM , Hurwitz M , Kane CJ , Kawachi MH , Kuettel M , Lee RJ , Meeks JJ , Penson DF , Plimack ER , Pow-Sang JM , Raben D , Richey S , Roach M 3rd , Rosenfeld S , Schaeffer E , Skolarus TA , Small EJ , Sonpavde G , Srinivas S , Strope SA , Tward J , Shead DA , Freedman-Cass DA
Prostate Cancer, Version 1.2016
J Natl Compr Canc Netw. 2016 Jan;14(1) :19-30
PMID: 26733552   
Back to previous list
Abstract
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naive disease.
Notes
Mohler, James L Armstrong, Andrew J Bahnson, Robert R D'Amico, Anthony Victor Davis, Brian J Eastham, James A Enke, Charles A Farrington, Thomas A Higano, Celestia S Horwitz, Eric M Hurwitz, Michael Kane, Christopher J Kawachi, Mark H Kuettel, Michael Lee, Richard J Meeks, Joshua J Penson, David F Plimack, Elizabeth R Pow-Sang, Julio M Raben, David Richey, Sylvia Roach, Mack 3rd Rosenfeld, Stan Schaeffer, Edward Skolarus, Ted A Small, Eric J Sonpavde, Guru Srinivas, Sandy Strope, Seth A Tward, Jonathan Shead, Dorothy A Freedman-Cass, Deborah A United States J Natl Compr Canc Netw. 2016 Jan;14(1):19-30.